Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives

Among the various strategies providing a cure for illness, cell-based therapies have caught the attention of the world with the advent of the “stem cell” era. Our inherent understanding indicates that stem cells have been in existence since the birth of multicellular organisms. However, the formal discovery of stem cells in the last century, followed by their intricate and extensive analysis, has led to clinical and translational efforts with the aim of using them in the treatment of conditions which don’t have a definitive therapeutic strategy, has fueled our interest and expectations. Technological advances in our ability to study their cellular components in depth, along with surface markers and other finer constituents, that were unknown until last century, have improved our understanding, leading to several novel applications. This has created a need to establish guidelines, and in that process, there are expressed understandings and views which describe cell therapy along lines similar to that of biologic products, drugs, and devices. However, the age-old wisdom of using cells as tools for curing illness should not be misled by recent knowledge, to make cell therapy using highly complex stem cells equal to factory-synthesized and reproducible chemical compounds, drugs, or devices. This article analyses the differences between these two entities from various perspectives.

[1]  Y. Tabata,et al.  Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. , 2012, Molecular pharmaceutics.

[2]  S. Karaman,et al.  Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells , 2012, Annals of Hematology.

[3]  M. Archdeacon,et al.  Autogenous bone graft: donor sites and techniques. , 2011, The Journal of bone and joint surgery. American volume.

[4]  M. Álvares-da-Silva,et al.  Relationship between ischemia/reperfusion injury and the stimulus of fibrogenesis in an experimental model: comparison among different preservation solutions. , 2011, Transplantation proceedings.

[5]  N. Habib,et al.  Autologous Bone Marrow Stem Cells in the Treatment of Chronic Liver Disease , 2011, International journal of hepatology.

[6]  D. Pamphilon,et al.  Concise Review: Expanding Roles for Hematopoietic Cellular Therapy and the Blood Transfusion Services , 2011, Stem cells.

[7]  Y. Tabata,et al.  Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[8]  A. Messias,et al.  Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived stem cells. , 2010, Arquivos brasileiros de oftalmologia.

[9]  Ben D. MacArthur,et al.  Mesenchymal and haematopoietic stem cells form a unique bone marrow niche , 2010, Nature.

[10]  Sharma Vk Basnet Rb,et al.  A Study of blood Requisiton and transfusion Practce in Surgery at bir Hospital , 2009 .

[11]  Donald W. Fink FDA Regulation of Stem Cell–Based Products , 2009, Science.

[12]  Michele De Luca,et al.  Isolation and production of cells suitable for human therapy: challenges ahead. , 2009, Cell stem cell.

[13]  S. Totey,et al.  Effect of holding time, temperature and different parenteral solutions on viability and functionality of adult bone marrow‐derived mesenchymal stem cells before transplantation , 2008, Journal of tissue engineering and regenerative medicine.

[14]  M. Rugge,et al.  Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters , 2007, Scandinavian journal of gastroenterology.

[15]  D. G. Halme,et al.  FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[16]  A. Parson The Long Journey from Stem Cells to Medical Product , 2006, Cell.

[17]  R. Franklin,et al.  Clinical canine spinal cord injury provides an opportunity to examine the issues in translating laboratory techniques into practical therapy , 2006, Spinal Cord.

[18]  S Louise Moffatt,et al.  Centennial review of corneal transplantation , 2005, Clinical & experimental ophthalmology.

[19]  P. Sanberg,et al.  Central Nervous System Entry of Peripherally Injected Umbilical Cord Blood Cells Is Not Required for Neuroprotection in Stroke , 2004, Stroke.

[20]  M. Yacoub,et al.  Targeted Cell Delivery Into Infarcted Rat Hearts by Retrograde Intracoronary Infusion: Distribution, Dynamics, and Influence on Cardiac Function , 2004, Circulation.

[21]  Elaine Fuchs,et al.  Stem cells of the skin epithelium , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Willerson,et al.  Adult stem cell therapy in perspective. , 2003, Circulation.

[23]  P. Anderlini,et al.  Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? , 2001, Blood.

[24]  J. Talmadge,et al.  Decrease in circulating hematopoietic progenitor cells by trapping in the pulmonary circulation. , 2001, Cytotherapy.

[25]  B. Vandekerckhove,et al.  Both CD34+38+ and CD34+38− Cells Home Specifically to the Bone Marrow of NOD/LtSZ scid/scid Mice but Show Different Kinetics in Expansion1 , 2001, The Journal of Immunology.

[26]  N. Tilney Transplantation and its biology: from fantasy to routine. , 2000, Journal of applied physiology.

[27]  P. Robey Stem cells near the century mark. , 2000, The Journal of clinical investigation.

[28]  Carlos F Fragachan,et al.  Pharmacologic antidotes in critical care medicine: A practical guide for drug administration , 1998, Critical care medicine.

[29]  T. Demmy,et al.  Organ preservation solutions in heart transplantation--patterns of usage and related survival. , 1997, Transplantation.

[30]  L. Pivacek,et al.  Effects of the temperature, the duration of frozen storage, and the freezing container on in vitro measurements in human peripheral blood mononuclear cells , 1996, Transfusion.

[31]  N. Chao,et al.  Bone marrow transplantation. Part I--Allogeneic. , 1989, The Western journal of medicine.

[32]  P. C. Steptoe,et al.  BIRTH AFTER THE REIMPLANTATION OF A HUMAN EMBRYO , 1978, The Lancet.

[33]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[34]  J. Till,et al.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. , 1961, Radiation research.

[35]  J. M. Lanao,et al.  Cell-based drug-delivery platforms. , 2012, Therapeutic delivery.

[36]  W. Piacibello,et al.  Proliferative senescence in hematopoietic stem cells during ex-vivo expansion. , 2005, Folia histochemica et cytobiologica.